STOCK TITAN

Clearmind Medicine completes CMND-100 Part C enrollment

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) completed patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100. Part C is a randomized, double-blind, placebo-controlled multiple-dose study assessing safety, tolerability and the compound’s pharmacokinetic profile.

The milestone follows enrollment of the first cohort in Part B, the first clinical evaluation of CMND-100 in patients with moderate-to-severe alcohol use disorder, and Part A’s safety and tolerability evaluation in healthy volunteers. Clearmind described Part A data as encouraging and expects Part C data to further inform its understanding of CMND-100.

Filing Explained

The 6-K incorporates the press release’s first three paragraphs into the company’s listed Form F-3 and Form S-8 registration statements, making the enrollment update part of those existing filings.

Patent families 19 patent families Clearmind's intellectual property portfolio
Granted patents 32 granted patents Included in Clearmind's intellectual property portfolio
neuroplastogens medical
"non-hallucinogenic psychedelic-derived neuroplastogens"
Neuroplastogens are drugs or molecules designed to boost the brain’s ability to reorganize and form new connections—think of them as medicines that help the brain ‘rewire’ itself after damage or during therapy. Investors watch them because successful neuroplastogens could become treatments for conditions like depression, Alzheimer’s, or brain injury, creating large markets and sharp changes in company value as trials, approvals, or setbacks occur.
Phase I/IIa clinical trial medical
"ongoing Phase I/IIa clinical trial evaluating CMND-100"
An early-stage clinical study that combines initial safety testing (Phase I) with a first look at whether a treatment shows signs of working in patients (Phase IIa). Investors watch these trials because they move a therapy from lab research toward proof that it can help people; successful results reduce technical risk and can unlock bigger trials, partnerships, regulatory attention, or increases in a company’s value — like a prototype test that determines whether a product should go into full production.
pharmacokinetic profile medical
"assess the safety, tolerability, and pharmacokinetic profile"
The pharmacokinetic profile describes how a drug moves through the body over time, including how quickly it is absorbed, how it spreads, and how it is eventually eliminated. For investors, understanding this profile helps gauge the drug’s effectiveness, safety, and the appropriate dosing schedule, which can influence a company’s potential success and market value. It provides insight into how a medication behaves, impacting its overall commercial viability.
double-blind medical
"randomized, double-blind, placebo-controlled multiple-dose study"
A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.
placebo-controlled medical
"randomized, double-blind, placebo-controlled multiple-dose study"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
moderate-to-severe AUD medical
"patients with moderate-to-severe AUD"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Has CMND completed enrollment for Part C of the CMND-100 trial?

Yes. Clearmind completed patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.

Where is CMND-100 Part C being conducted?

The trial is being conducted at sites across the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: November 2026

 

Commission file number: 001-41557

 

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

 

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on November 16, 2026, titled “Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone.”

 

The first three paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   Press release titled: “Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Clearmind Medicine, Inc.
  (Registrant)
     
Date: November 16, 2026 By: /s/ Adi Zuloff-Shani
  Name:  Adi Zuloff-Shani
  Title: Chief Executive Officer

 

3

 

Exhibit 99.1

 

Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone

 

Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.

 

The completion of patient enrollment for Part C marks another important milestone in Clearmind’s clinical development program and reflects the continued strong execution of its Phase I/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability data from Part A in healthy volunteers.

 

Part C is a randomized, double-blind, placebo-controlled multiple-dose study designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100. The trial is being conducted at premier clinical research sites across the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

 

“The successful completion of Part C enrollment demonstrates the continued momentum of our CMND-100 program and represents another important milestone for Clearmind,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “The data generated in this cohort is expected to further enhance our understanding of CMND-100’s safety, tolerability, and pharmacokinetic profile to help support the advancement of our proprietary non-hallucinogenic treatment candidate toward future development milestones.”

 

About Clearmind Medicine Inc.

 

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

 

The Company’s intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

 

 

 

 

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

 

For further information, visit: https://www.clearmindmedicine.com or contact:

 

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

 

Forward-Looking Statements:

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated data from Part C of the Phase I/IIa clinical trial, the potential for such data to further inform the Company’s understanding of CMND-100’s safety, tolerability and pharmacokinetic profile, and the continued clinical development and advancement of CMND-100 toward future development milestones. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading